Fractyl Health, Inc. (NASDAQ:GUTS) Given Consensus Rating of “Hold” by Brokerages

Fractyl Health, Inc. (NASDAQ:GUTS) has earned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $5.40.

GUTS has been the topic of a number of research analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a report on Tuesday, May 12th.

Fractyl Health Price Performance

NASDAQ GUTS opened at $0.66 on Wednesday. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $2.90. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The firm has a market capitalization of $105.36 million, a PE ratio of -0.51 and a beta of 2.34. The company’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $1.08.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities research analysts forecast that Fractyl Health will post -0.6 EPS for the current fiscal year.

Institutional Trading of Fractyl Health

A number of large investors have recently added to or reduced their stakes in GUTS. Woodline Partners LP boosted its holdings in Fractyl Health by 47.2% during the first quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after buying an additional 165,786 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Fractyl Health during the second quarter worth approximately $129,000. General Catalyst Group Management LLC bought a new stake in Fractyl Health during the second quarter worth approximately $7,912,000. Jane Street Group LLC bought a new stake in Fractyl Health during the second quarter worth approximately $31,000. Finally, Osaic Holdings Inc. boosted its holdings in Fractyl Health by 460.3% during the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after buying an additional 49,000 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.